Table 1 Demographic and clinical characteristics of the study cohort
From: Prostate cancer presentation and management in the Middle East
Age, median, range | 70 (50–84) |
|---|---|
Reason for prostate cancer evaluation, No. (%) | |
Routine surveillance | 254 (22) |
Patient had symptoms | 882 (78) |
AJCC tumor stage, No. (%) | |
T1c | 90 (10) |
T2a | 110 (12) |
T2b | 166 (18) |
T2c | 235 (25) |
T3a | 148 (16) |
T3b | 90 (10) |
T4 | 86 (9) |
AJCC nodal stage, No. (%) | |
N0 | 556 (64) |
N1 | 311 (36) |
AJCC metastatic stage, No. (%) | |
M0 | 587 (52) |
M1a | 30 (3) |
M1b | 268 (24) |
M1c | 251 (22) |
AJCC stage | |
Stage I | 86 (7) |
Stage II | 218 (19) |
Stage III | 223 (20) |
Stage IV | 609 (54) |
Gleason score, No. (%) | |
6 (3 + 3) | 106 (11) |
7 (3 + 4) | 169 (18) |
7 (4 + 3) | 191 (20) |
8 (4 + 4, 3 + 5, or 5 + 3) | 225 (24) |
9 or 10 (4 + 5, 5 + 4, or 5 + 5) | 246 (26) |
Baseline PSA, mean | 83.4 |
Diagnostic Imaging, No. (%) | |
Bone scan* | 4 (0) |
CT scan* | 42 (4) |
MRI* | 148 (13) |
PSMA-PET, with or without other imaging | 372 (33) |
US alone* | 54 (5) |
Bone scan + CT scan | 93 (8) |
Bone Scan + CT scan + MRI | 272 (24) |
No imaging | 151 (13) |